Lethal osteogenesis imperfecta: abnormal collagen metabolism and biochemical characteristics of hypophosphatasia
- PMID: 3181205
- DOI: 10.1007/BF00442478
Lethal osteogenesis imperfecta: abnormal collagen metabolism and biochemical characteristics of hypophosphatasia
Abstract
We have examined collagen from a patient with the rare type IIC form of perinatally lethal osteogenesis imperfecta, in whom biochemical characteristics of hypophosphatasia were also apparent. In addition to normal alpha 1(I) and alpha 2(I) chains, there were chains overmodified along their lengths. Unexpectedly, the thermal stability of molecules containing these chains was normal. This suggests the existence of a structural mutation causing delayed triple helix formation, situated in either the alpha 1(I) or alpha 2(I) C-terminal propeptide. Since collagen synthesised by fibroblasts from each of the patient's parents was normal, the mutation was probably newly arising and dominant. In contrast to other reported cases of lethal osteogenesis imperfecta, not only was the secretion of collagen by cultured fibroblasts considerably retarded, but that of non-collagenous proteins was also severely impaired.
Similar articles
-
Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly.J Biol Chem. 1995 Apr 14;270(15):8642-9. doi: 10.1074/jbc.270.15.8642. J Biol Chem. 1995. PMID: 7721766
-
Collagen defects in lethal perinatal osteogenesis imperfecta.Biochem J. 1986 Dec 15;240(3):699-708. doi: 10.1042/bj2400699. Biochem J. 1986. PMID: 3827862 Free PMC article.
-
Localization of a structural defect in type I procollagen in a patient affected with the severe non-lethal form of Osteogenesis imperfecta.Ital J Biochem. 1987 Jul-Aug;36(4):256-66. Ital J Biochem. 1987. PMID: 3429209
-
Osteogenesis imperfecta and other heritable disorders of bone.Baillieres Clin Endocrinol Metab. 1997 Apr;11(1):195-213. doi: 10.1016/s0950-351x(97)80601-5. Baillieres Clin Endocrinol Metab. 1997. PMID: 9222492 Review.
-
New diagnostic modalities and emerging treatments for neonatal bone disease.Early Hum Dev. 2018 Nov;126:32-37. doi: 10.1016/j.earlhumdev.2018.08.014. Epub 2018 Sep 3. Early Hum Dev. 2018. PMID: 30190174 Review.
Cited by
-
Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.Adv Exp Med Biol. 2019;1148:279-322. doi: 10.1007/978-981-13-7709-9_13. Adv Exp Med Biol. 2019. PMID: 31482504 Review.
-
Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. Nat Rev Endocrinol. 2016. PMID: 26893260 Review.
-
Brittle cornea syndrome: an heritable connective tissue disorder distinct from Ehlers-Danlos syndrome type VI and fragilitas oculi, with spontaneous perforations of the eye, blue sclerae, red hair, and normal collagen lysyl hydroxylation.Eur J Pediatr. 1990 Apr;149(7):465-9. doi: 10.1007/BF01959396. Eur J Pediatr. 1990. PMID: 2112090
-
Biosynthesis of recombinant human pro-alpha 1(III) chains in a baculovirus expression system: production of disulphide-bonded and non-disulphide-bonded species containing full-length triple helices.Biochem J. 1995 Dec 15;312 ( Pt 3)(Pt 3):847-53. doi: 10.1042/bj3120847. Biochem J. 1995. PMID: 8554530 Free PMC article.
-
Hypophosphatasia: an overview of the disease and its treatment.Osteoporos Int. 2015 Dec;26(12):2743-57. doi: 10.1007/s00198-015-3272-1. Epub 2015 Aug 6. Osteoporos Int. 2015. PMID: 26245849 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical